- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | RADIOPHARM THERANOSTICS LIMITED: Change in substantial holding | 1 | ASX | ||
| 23.12.25 | RADIOPHARM THERANOSTICS LIMITED: Notification of cessation of securities - RAD | 1 | ASX | ||
| 19.12.25 | RADIOPHARM THERANOSTICS LIMITED: Change of Director's Interest Notice (RC) | - | ASX | ||
| 19.12.25 | RADIOPHARM THERANOSTICS LIMITED: Change of Director's Interest Notice (PH) | - | ASX | ||
| 19.12.25 | RADIOPHARM THERANOSTICS LIMITED: Change of Director's Interest Notice (IT) | - | ASX | ||
| 19.12.25 | RADIOPHARM THERANOSTICS LIMITED: Notification regarding unquoted securities - RAD | - | ASX | ||
| 18.12.25 | RADIOPHARM THERANOSTICS LIMITED: Proposed issue of securities - RAD | 1 | ASX | ||
| 18.12.25 | RADIOPHARM THERANOSTICS LIMITED: RAD announces establishment of At-The-Market Equity Facility | 13 | ASX | ||
| RADIOPHARM THERANOSTICS Aktie jetzt für 0€ handeln | |||||
| 18.12.25 | RADIOPHARM THERANOSTICS LIMITED: Non-compliance with ASX Listing Rule 7.1 | 1 | ASX | ||
| 15.12.25 | Radiopharm (RADX) Sees Slight Pessimism From Analysts | 3 | Insider Monkey | ||
| 15.12.25 | Radiopharm Theranostics: 92 % der Probanden erreichen primären Endpunkt in RAD101-Studie | 20 | Investing.com Deutsch | ||
| 15.12.25 | Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases | 6 | GlobeNewswire (USA) | ||
| 15.12.25 | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.12.25 | RADIOPHARM THERANOSTICS LIMITED: RAD101 interim Phase 2b data - 92% achieve primary endpoint | 1 | ASX | ||
| 10.12.25 | RADIOPHARM THERANOSTICS LIMITED: Ceasing to be a substantial holder PH | 1 | ASX | ||
| 09.12.25 | RADIOPHARM THERANOSTICS LIMITED: Notice Under Section 708A | 1 | ASX | ||
| 09.12.25 | RADIOPHARM THERANOSTICS LIMITED: Application for quotation of securities - RAD | - | ASX | ||
| 09.12.25 | RADIOPHARM THERANOSTICS LIMITED: Application for quotation of securities - RAD | - | ASX | ||
| 09.12.25 | RADIOPHARM THERANOSTICS LIMITED: New Class Options Range of Units and Top 20 Holders | 1 | ASX | ||
| 04.12.25 | RADIOPHARM THERANOSTICS LIMITED: Application for quotation of securities - RAD | - | ASX |
1 2 3 4 5 Weiter >>
106 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VENTYX BIOSCIENCES | 13,830 | +0,73 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| QIAGEN | 41,290 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 23,280 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,350 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 41,590 | 0,00 % | Regencell Bioscience is the top performing pharma stock YTD | ||
| ALUMIS | 18,170 | 0,00 % | What's Going On With Alumis Stock Thursday? | ||
| PRAXIS PRECISION MEDICINES | 294,38 | 0,00 % | Praxis Precision Prices $575 Mln Public Offering At $260/shr | ||
| PHATHOM PHARMACEUTICALS | 15,630 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| IMMUNEERING | 4,730 | 0,00 % | Immuneering Corporation: Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP | - Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently... ► Artikel lesen | |
| EVOTEC | 6,338 | +0,76 % | EQS-News: Evotec SE: Evotec ernennt Dr. Sarah Fakih als EVP, Leiterin Global Communications und Investor Relations | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec ernennt Dr. Sarah Fakih als EVP, Leiterin Global Communications und Investor Relations
01.01.2026 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 25,310 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| ERASCA | 5,840 | 0,00 % | Erasca stock pulls back after 25% jump, Stifel cites competitor data | ||
| AVIDITY BIOSCIENCES | 72,35 | -0,03 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| BIONTECH | 84,60 | -1,34 % | BYD gegen Tesla! KI-Profiteure BioNTech und Rio Tinto Partner Aspermont! Aktien für 2026? | Paukenschlag kurz vor Silvester! BYD hat Tesla vom E-Auto-Thron gestoßen. Die Chinesen sind jetzt auch Weltmarktführer bei rein elektrischen Fahrzeugen. Doch die Aktie hat 2025 klar enttäuscht. Ein... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,700 | -3,29 % | Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates |
Das Unternehmen RADIOPHARM THERANOSTICS LIMITED ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,820 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RADIOPHARM THERANOSTICS LIMITED ADR finden Sie auf Wallstreet Online.